The opioid crisis exposed how well-intentioned care, shaped by misaligned incentives, can cause widespread harm. A similar pattern is now emerging with antidepressants.
The opioid crisis has taught us the lesson that well-intentioned medicine, when paired with misaligned incentives, can produce devastating public health outcomes. What was introduced in the 1990s as revolutionary pain prescriptions, turned out to become a health epidemic catalyzed by large pharmaceutical companies selling a product in which there was direct knowledge that long-term usage led to difficulties in patients withdrawing. Prescribing physicians contributed to the epidemic not out of greed or malintent, but sympathy. A place of…
Share your email below to keep reading — it’s free.
Your information is secure. View our Privacy Policy.
CRG’s Brian Englander sat down with Joe Catanese, CEO of Calyxo, to discuss the kidney stone market, his career, and how his team is working to change kidney stone treatment through its innovative technology, ultimately improving the quality of care for patients who suffer from kidney stones.